Initial management of high risk early stage prostate cancer: Radiation

Eric M. Horwitz, Steven J. Feigenberg, Alan Pollack

Research output: Chapter in Book/Report/Conference proceedingChapter


Because there are many treatment options for nonmetastatic prostate cancer, it is vitally important to define risk and determine a patient’s prognosis to aid in the treatment design. Risk is defined many ways, although the single most important prognostic variable is a person’s pretreatment PSA level.1 Other important variables include Gleason score, T stage, and radiation dose.2 At Fox Chase Cancer Center (FCCC) and elsewhere, these variables are used to categorize men into multiple risk groups.3-5 Patients with low-risk disease include those with PSA (10 ng/mL, Gleason score 2 to 6 and T1c/T2a disease. The high-risk group consists of patients having one of the following highrisk features: Gleason score 8 to 10, PSA greater than 20 ng/mL, or T3/T4 disease. Intermediate-risk patients do not fit into either of the above risk groups. Treatment options for low-and high-risk disease are discussed elsewhere. The focus of this chapter is on radiation treatment options for men with intermediate risk prostate cancer.

Original languageEnglish (US)
Title of host publicationProstate Cancer
Subtitle of host publicationPrinciples and Practice
PublisherCRC Press
Number of pages9
ISBN (Electronic)9780203624326
ISBN (Print)9781841844589
StatePublished - Jan 1 2005
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Initial management of high risk early stage prostate cancer: Radiation'. Together they form a unique fingerprint.

Cite this